HCM
MACK

Highbridge Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Highbridge Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,013
Closed -$85K – 1870
2016
Q2 		$85K Buy
+2,013
New +$110K ﹤0.01% 1316
2016
Q1 		– Sell
-11,173
Closed -$583K – 2034
2015
Q4 		$695K Buy
+11,173
New +$786K 0.01% 885

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Highbridge Capital Management's MACK Position: Q3 2016 in Review

Highbridge Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2016, closing a stake of 2,013 shares — an estimated $85K sold.

Highbridge Capital Management first reported a position in MACK in Q4 2015 and held it in 2 quarters. The position peaked at $695K in Q4 2015. 128 funds tracked by Wall St. Rank hold MACK as of Q3 2016.

  • Highbridge Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 2,013 Merrimack Pharmaceuticals, Inc. shares in Q3 2016, an estimated $85K.
  • Highbridge Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $695K in Q4 2015.
  • 128 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2016.

Based on Highbridge Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.